An Atlas of Altered Expression of Deubiquitinating Enzymes in Human Cancer
Author Information
Author(s): Luise Chiara, Capra Maria, Donzelli Maddalena, Mazzarol Giovanni, Jodice Maria Giovanna, Nuciforo Paolo, Viale Giuseppe, Di Fiore Pier Paolo, Confalonieri Stefano
Primary Institution: IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy
Hypothesis
DUB dysregulation is a frequent event in cancer and may have implications for therapeutic approaches based on DUB inhibition.
Conclusion
The study demonstrates that DUB dysregulation is common in various human cancers and suggests potential therapeutic targets.
Supporting Evidence
- 22 DUBs were found to be dysregulated in at least one type of cancer.
- Significant correlations were observed between DUB expression and clinical parameters indicative of aggressive disease.
- Selected DUBs were validated in large cohorts of tumor samples.
Takeaway
This study looked at how certain proteins that help control other proteins are messed up in cancer, which could help doctors find new ways to treat it.
Methodology
The study used in situ hybridization on tissue microarrays to analyze the expression of 89 DUB-encoding genes in various human cancers.
Limitations
The study primarily focused on expression levels and did not extensively investigate genetic alterations affecting DUBs.
Participant Demographics
The study included specimens from various normal and malignant tumor tissues, often from the same patients.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website